Navigation Links
ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
Date:9/24/2010

qualification under the securities laws of any such jurisdiction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. Pursuant to the terms of the registration rights agreement to be entered into at the closing, Oncothyreon will agree to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.

Forward-Looking Statements

This press release contains statements that are forward-looking, including statements regarding Oncothyreon's expectations regarding the amount and expected uses of the proceeds that will be received in the private placement, the expected closing date of the private placement transaction, and the anticipated filing of a registration statement to cover the resale of the shares sold in the private placement. Although Oncothyreon believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. Forward-looking statements involve risks and uncertainties, many of which are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause actual results to differ materially from those projected in forward-looking statements. For a detailed description of such risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncot
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
2. Oncothyreon reports second quarter 2010 financial results
3. Oncothyreon announces second quarter 2010 financial results conference call
4. Oncothyreon announces presentations at upcoming investor conferences in June
5. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
6. Oncothyreon reports full year and fourth quarter 2009 financial results
7. Oncothyreon reports first quarter 2010 financial results
8. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
9. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
10. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
11. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... CORD:USE Cord Blood Bank – www.corduse.com ... entered into an Equity and Exclusive Services Agreement with ... of patented technologies for the isolation of human cord ... is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that the ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... focusing on commercializing market-relevant biohealth innovations and increasing access ... , announced today that venture capitalist, Tania Fernandez ... strategic advisor. Dr. Fernandez will be a member of ... which will provide up to $50 million in seed ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... Walton-Bowen, M.Sc.,C.Stat, a biostatistician with more than ... industries, has joined Abt Bio-Pharma,Solutions, Inc. (ABS), ... trials and regulatory submissions in all phases ... Walton-Bowen,s,experience encompasses clinical operations, data management, programming,statistical ...
... teams vie for cash prizes awarded for nation,s best ... ... The National Inventors Hall of,Fame Foundation today announced the ... finalists includes,undergraduate and graduate students from across the country whose,inventions ...
... on Schedule, SAN MATEO, Calif., Oct. 22 ... company focused on developing and,commercializing novel pain management ... drug application (NDA) with the U.S. Food and ... product,candidate, NGX-4010, for the management of pain due ...
Cached Biology Technology:Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics 2Collegiate Inventors Competition(R) Recognizes Top Student Inventors 2Collegiate Inventors Competition(R) Recognizes Top Student Inventors 3Collegiate Inventors Competition(R) Recognizes Top Student Inventors 4NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN) 2NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN) 3NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN) 4
(Date:9/29/2014)... ramosum , coupled with a high-fat diet, may cause animals ... mBio , the online open-access journal of the American ... German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that ... gained weight when fed a high-fat diet. Mice that did ... when consuming a high-fat diet, and mice that had ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
(Date:9/29/2014)... DETROIT In order to support the world,s ... chemicals, polymers and more, new and more efficient ... team of researchers, including several from Wayne State ... of a new grant from the National Science ... Guided Design of Multicomponent Materials for Electrocatalytic Cascade ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Wayne State research aims to develop new, more efficient catalytic materials 2
... identified a gene they say is a strong candidate ... maladies associated with the natural flux in hormones during ... the Proceedings of the National Academy of Sciences ... that a common human variant of the gene increases ...
... Vesicular stomatitis virus, or VSV, has long been a model ... RNA viruses, which include viruses that cause influenza, measles and ... VSV has the potential to be genetically modified to serve ... cells while sparing healthy cells, and as a potent vaccine ...
... REDWOOD CITY, Calif. , Feb. 9 ... solutions, continues to expand its leadership in fingerprint biometrics ... of the popular Digital Dining ™ restaurant Point-of-Sale ... will be unveiled at the Digital Dining National Dealer ...
Cached Biology News:Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Researchers reveal 3-D structure of bullet-shaped virus with potential to fight cancer, HIV 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 3
... Acid Resistant SpeedVac Model SPD131DDA , ... The SPD131DDA is designed to handle the rigors ... new slim design, digital display, dual independent timers, ... coated chamber and vapor pathway. , , ...
... The University of New South Wales, Sydney, Australia ... Australia This is the Fourth Edition of this ... is a large format version (330 x ... 3rd edition. This product number includes the ...
... RC10 series of vacuum concentrators/centrifugal evaporators offers ... allied to rapid and safe concentration of ... combined with oil-free or high vacuum pumps, ... wide selection of rotors (eliminating sample loss ...
... Thermo Electron's most advanced personal gradient option ... use sophisticated onboard software and a large ... offer performance, accuracy and simplicity in thermal ... customer driven features built up on years ...
Biology Products: